慢性病及其治疗药物可能会影响肺癌患者术后5年生存率

doi:10.5246/jcps.2017.02.014

中国药学(英文版) ›› 2017, Vol. 26 ›› Issue (2): 147-155.DOI: 10.5246/jcps.2017.02.014

慢性病及其治疗药物可能会影响肺癌患者术后5年生存率

施亮¹, 王增¹, 俞婷婷^2*, 夏亮¹

1. 浙江省肿瘤医院, 浙江杭州 310022
2. 杭州市西湖区中西医结合医院, 浙江杭州 310030

收稿日期:2016-11-15 修回日期:2016-11-28 出版日期:2017-02-28 发布日期:2016-12-18
通讯作者: +86-15068193184, E-mail: 435517746@qq.com
基金资助:
General Research Program of Medical Health in Zhejiang Province (Grant No. 2014KYB039), Zhejiang Provincial Program for the Zhejiang Medical and Health Science and Technology Program (Grant No. 2015KYB071), Scientific Research Fund Project of Integrated Chinese and Western Medicine Institute in Zhejiang Province (Grant No. 2014LYK021), Science and Technology in Zhejiang Province Chinese Medicine Program (Grant No. 2016ZA038), and 1022 Talent Training Program of Zhejiang Cancer Hospital.

Chronic disease and its therapeutic drugs may effect on the postoperative 5-year survival rate of lung cancer patients

Liang Shi¹, Zeng Wang¹, Tingting Yu^2*, Liang Xia¹

1. Zhejiang Cancer Hospital, Hangzhou 310022, China
2. Xihu District Hangzhou SanDu Town Community Health Service Center, Hangzhou 310030, China

Received:2016-11-15 Revised:2016-11-28 Online:2017-02-28 Published:2016-12-18
Contact: +86-15068193184, E-mail: 435517746@qq.com
Supported by:
General Research Program of Medical Health in Zhejiang Province (Grant No. 2014KYB039), Zhejiang Provincial Program for the Zhejiang Medical and Health Science and Technology Program (Grant No. 2015KYB071), Scientific Research Fund Project of Integrated Chinese and Western Medicine Institute in Zhejiang Province (Grant No. 2014LYK021), Science and Technology in Zhejiang Province Chinese Medicine Program (Grant No. 2016ZA038), and 1022 Talent Training Program of Zhejiang Cancer Hospital.

摘要/Abstract

摘要：

本研究旨在探讨非小细胞肺癌(NSCLC)I~III期患者术后5年生存率的影响因素。我们收集了2009年1月至2009年12月间经组织学证实的腺癌或鳞状细胞癌的NSCLC术后患者共220例,且存活期大于3个月。影响因素有多个变量,如年龄、性别、吸烟、酒精、肥胖、糖尿病、高血压、抗糖尿病药物、肿瘤分期、病理学、治疗方式、发病部位(左侧或右侧)以及脂质水平。通过单变量分析,我们发现肿瘤分期与I~III期NSCLC患者的5年生存率相关。此外,糖尿病、高血压和发病部位(左侧或右侧)分别与NSCLC患者I期, II期和III期的5年生存率相关。由此可得,慢性病及其治疗药物可能对肺癌患者术后5年生存率具有潜在影响。

关键词: 非小细胞, 肺癌, 5年生存率, 影响因素

Abstract:

In this study, we aimed to investigate the influencing factors of postoperative 5-year survival rate in non small-cell lung cancer (NSCLC) patients with stage I-III. We enrolled 220 patients who underwentsurgical operation and survived longer than 3 months, with histologically confirmed adenocarcinoma or squamous cell carcinoma from Jan. 2009 to Dec. 2009. Multiple variables, like age, gender, smoking, alcohol, obesity, family history of cancer, diabetes, hypertension, antidiabetic drugs, tumor staging, pathology, treatments, surgical side as well as lipid levels, were selected. We found that tumor staging was associated with 5-year survival rate of stage I-III NSCLC patients by univariate analysis. Furthermore, diabetes mellitus, hypertension andsurgical side were associated with the overall survival of NSCLC patients with stage I, stageⅡand stageIII, respectively. In conclusion, the status of chronic disease had potential effect on the postoperative 5-year survival rate of lung cancer patients.

Key words: Non small-cell, Lung cancer, 5-Year survival rate, Influencing factors

中图分类号:

R969

Supporting:

施亮, 王增, 俞婷婷, 夏亮. 慢性病及其治疗药物可能会影响肺癌患者术后5年生存率[J]. 中国药学(英文版), 2017, 26(2): 147-155.

Liang Shi, Zeng Wang, Tingting Yu, Liang Xia. Chronic disease and its therapeutic drugs may effect on the postoperative 5-year survival rate of lung cancer patients[J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(2): 147-155.

参考文献

[1] Siegel, R.; Naishadham, D.; Jemal, A. Cancer J. Clin. 2013, 63, 11-30.
[2] Owonikoko, T.K.; Ragin, C.C.; Belani, C.P. J. Clin. Oncol. 2007, 25, 5570-5577.
[3] Zimmermann, F.B.; Molls, M.; Jeremic, B. Semin. Surg. Oncol. 2003, 21, 122-127.
[4] Awabata, N.; Miyaoka, E.; Asamura, H. J. Thorac. Oncol. 2011, 6, 1229-1235.
[5] Asamura, H.; Goya,T.; Koshiishi,Y. J. Thorac. Oncol. 2008, 3, 46–52
[6] Brundage, M.D.; Davies, D.; Mackillop, W. J. Chest. 2002, 122, 1037-1057.
[7] Birim, O.; Zuydendorp, H.M.; Maat, A.P. Ann Thorac. Surg. 2003, 76, 1796-1801.
[8] Park, C.; Lee, I.J.; Jang, S.H. J. Thorac. Dis. 2014, 6, 1420-1428.
[9] Myrdal, G.; Gustafsson, G.; Lambe, M. Eur. J. Cardiothorac. Surg. 2001, 20, 694-699.
[10] Uehara, H.; Nakao, M.; Mun, M. Ann Thorac. Cardiovasc. Surg. 2015, 21, 345-353.
[11] Zimmermann, F.B.; Molls, M.; Jeremic, B. Semin. Surg. Oncol. 2003, 21, 122-124.
[12] Uramoto, H.; Tanaka, F. Transl. Lung. Cancer Res. 2014, 3, 242-249.
[13] Hotta, K.; Fujiwara, Y.; Kiura, K.J. Thoracic. Oncol. 2007, 5, 402-407.
[14] Jeremic, B.; Milicic, B.; Dagovic, A.J. Cancer. Res. Clin. Oncol. 2003, 129, 114-122.
[15] Falcone, A.J. Cancer Res. Clin. Oncol. 2008, 134, 1143-1149.
[16] Hashizume, S.; Nagayasu, T.; Hayashi, T. Lung Cancer. 2009, 65, 363-370.
[17] Sawada, S.; Yamashita, N.; Suehisa, H. Chest. 2013, 144, 1238-1244.
[18] Brundage, M.D.; Davies, D.; Mackillop. W. J. Chest. 2002, 122, 1037-1057.
[19] Goldstraw, P.; Crowley, J.; Chansky, K. J. Thorac. Oncol. 2007, 2, 706-714.
[20] Huang, Y.C.; Lin, J.K.; Chen, W.S. J. Cancer. Res. Clin. Oncol. 2011, 137, 211-220.
[21] Sperti, C.; Pasquali, C.; Piccoli, A. Br. J. Surg. 1996, 83, 625-631.
[22] Toyoda, H.; Kumada, T.; Nakano, S. Cancer. 2001, 91, 957-963.
[23] Dawson, S.I. Cancer. 2004, 100, 149-155.
[24] Spranger, J.; Kroke, A.; Mohlig, M. Diabetes. 2003, 52, 812-817.
[25] Wang, Y.; James, M.; Wen, W. Mol. Cancer Ther. 2010, 9, 3074-3082.
[26] Zhou, R.; Myers, Y. J. Clin. Invest. 2001, 108, 1167-1174.
[27] Dowling, M.; Zakikhani, I.G.; Fantus, G. Cancer Res. 2007, 67, 10804-10812.
[28] Lin, C.C.; Yeh, H.; Huang, L. Am. J. Respiratory Cell Molecul. 2013, 49, 241-250.
[29] Teixeira, S.F.; Guimar es, I.S.; Madeira, K.P. Jornal Brasileiro De Pneumologia Publicacao Oficial Da Sociedade Brasileira De Pneumologia E Tisilogia. 2013, 39, 644-649.
[30] Mishra, P.K.; Pandey, R.; Shackcloth, M.J. Eur. J. Cardiothorac. Surg. 2009, 35, 439-443.
[31] Moro-Sibilot, D.; Aubert, A.; Diab, S. Eur. Respir. J. 2005, 26, 480-486.
[32] Alex, B. J. Hypertension. 2005, 23, 1473-1475
[33] Schuller, H.M. Oncotarget. 2010, 1, 466-469
[34] Marrer, é.; Wagner, A.; Montaye, M. Eur. J. Cancer Prev. 2013, 22 , 286-293.
[35] Motoji, S.; Noriko, T.; Makiko, N.M. PLoS One. 2012, 7, e31954.
[36] Motta, M.; Giugno, I.; Ruello, P. Minerva Med. 2001, 92, 301-305.
[37] Stojiljkovic, D.; Santrac, N.; Goran, M. J. Buon. 2016, 21, 221-226.
[38] Yano, M.; Yoshida, J.; Koike, T. World J. Surg. 2016, 1-10.
[39] Zhang, T.; Jiang, Y.; Qu, X. PLoS One. 2014, 9, e111494.

慢性病及其治疗药物可能会影响肺癌患者术后5年生存率

Chronic disease and its therapeutic drugs may effect on the postoperative 5-year survival rate of lung cancer patients

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王可欣, 田胜男, 王佳, 靳瑾, 王婷婷, 张丽藏, 刘焕龙. 基于KAP理论的石家庄市区居民用药风险调查研究[J]. 中国药学(英文版), 2023, 32(9): 755-763.
[2]	刘文夏, 马俊, 杨照, 江滨. 中国仿制药替代影响因素分析——基于"4 + 7"带量采购精神科用药患者角度[J]. 中国药学(英文版), 2023, 32(4): 317-321.
[3]	阳丽梅, 王丽满, 黄旭慧, 庄捷. 华法林通过调控Gas6/Axl/PI3K/Akt/NF-κB通路影响肺癌细胞株的增殖和凋亡[J]. 中国药学(英文版), 2023, 32(3): 190-199.
[4]	苏俐玫, 毛溪悦, 阳丽梅. 肺癌患者静脉血栓栓塞预防的疗效与安全性的meta分析[J]. 中国药学(英文版), 2023, 32(10): 852-860.
[5]	彭词艳, 陈景, 李斯妮, 李健和, 彭六保. 后疫情时代中南地区脑卒中患者经济负担及影响因素研究[J]. 中国药学(英文版), 2022, 31(7): 545-555.
[6]	骆少红, 董凉凉, 李逸元, 徐丹, 陈敏. 酪氨酸激酶抑制剂 (吉非替尼、厄洛替尼、阿法替尼和奥希替尼)一线治疗表皮生长因子受体突变的晚期非小细胞肺癌的成本-效果分析[J]. 中国药学(英文版), 2021, 30(3): 253-263.
[7]	李佳乐, 杨艳, 黄兆耆, 莫小兰. 结合雌激素治疗幼女阴唇粘连的效果评价及影响因素分析[J]. 中国药学(英文版), 2021, 30(12): 976-985.
[8]	林珅, 饶欣, 李逸元, 翁秀华, 王长连. 非鳞非小细胞肺癌患者二线化疗方案的成本-效果分析[J]. 中国药学(英文版), 2020, 29(8): 542-553.
[9]	王壮飞, 管晓东, 周越, 韩晟, 姚鹏, 史录文. 中国中老年人自我药疗发生率及影响因素研究：基于CHARLS 2011年, 2013年和2015年的面板数据[J]. 中国药学(英文版), 2019, 28(6): 430-438.
[10]	刘疆燕, 李秀男, 张晓雪, 黄豪雁, 陈利清, 崔京浩, 曹青日. 改善双氯芬酸钾颗粒及胶囊剂稳定性的工艺优化研究[J]. 中国药学(英文版), 2018, 27(2): 82-91.
[11]	管晓东, 马莉莉, 王国英, 海沙尔江·吾守尔, 满春霞, 韩晟, 史录文. 中国2型糖尿病患者胰岛素注射笔用针头重复使用的影响因素研究[J]. 中国药学(英文版), 2018, 27(1): 51-58.
[12]	吕方冰, 于克炜, 高雯雯, 俞淑文. 贝伐珠单抗联用厄洛替尼对比贝伐珠单抗单用在晚期非小细胞肺癌维持治疗中的成本-效用[J]. 中国药学(英文版), 2017, 26(6): 447-454.
[13]	赵德华, 楚明明, 陈静, 王继生. 吉西他滨标准剂量30分钟快速输注与低剂量延时输注治疗进展期非小细胞肺癌的Meta分析[J]. 中国药学(英文版), 2017, 26(10): 763-770.
[14]	花明, 冀希炜, 李润涛, 季双敏, 李健, 姚庆宇, 王丽杰, 郝方然, 卢炜, 周田彦. TM208治疗非小细胞肺癌移植瘤的药物动力学-药效动力学模型[J]. 中国药学(英文版), 2016, 25(7): 502-511.
[15]	牟珍珍, 王思媛, 苏清虹, 袁茵, 李静云, 王丽杰, 姚庆宇, 季双敏, 卢炜, 周田彦. 卡博替尼增强EGFR野生型NSCLC细胞对埃罗替尼的响应以及两药序贯联用的药效学模型研究[J]. 中国药学(英文版), 2016, 25(11): 799-813.